+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Fragile X Syndrome - Pipeline Review, H2 2018

  • ID: 4649592
  • Drug Pipelines
  • 135 pages
  • Global Markets Direct
1 of 4

FEATURED COMPANIES

  • Aelis Farma SAS
  • DRI Biosciences Corp
  • Epigen Biosciences Inc
  • GlaxoSmithKline Plc
  • Healx Ltd
  • Neuron Biopharma SA
  • MORE
Fragile X Syndrome - Pipeline Review, H2 2018

Summary:

This latest Pharmaceutical and Healthcare disease pipeline guide Fragile X Syndrome - Pipeline Review, H2 2018, provides an overview of the Fragile X Syndrome (Genetic Disorders) pipeline landscape.

Fragile X syndrome is a genetic condition that causes a range of developmental problems including learning disabilities and cognitive impairment. Fragile X syndrome is caused by a change in a gene called FMR1. Fragile X syndrome occurs both in male and female. Symptoms include delay in crawling, walking, or twisting, hyperactive or impulsive behavior, speech and language delay and intellectual disability.

Report Highlights:

This latest pipeline guide Fragile X Syndrome - Pipeline Review, H2 2018, provides comprehensive information on the therapeutics under development for Fragile X Syndrome (Genetic Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Fragile X Syndrome (Genetic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Fragile X Syndrome and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 2, 5, 2, 14, 3 and 1 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 3 molecules, respectively.

Fragile X Syndrome (Genetic Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Fragile X Syndrome (Genetic Disorders).
  • The pipeline guide reviews pipeline therapeutics for Fragile X Syndrome (Genetic Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Fragile X Syndrome (Genetic Disorders) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Fragile X Syndrome (Genetic Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Fragile X Syndrome (Genetic Disorders)
Reasons to buy:
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Fragile X Syndrome (Genetic Disorders).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Fragile X Syndrome (Genetic Disorders) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • Aelis Farma SAS
  • DRI Biosciences Corp
  • Epigen Biosciences Inc
  • GlaxoSmithKline Plc
  • Healx Ltd
  • Neuron Biopharma SA
  • MORE
Introduction

Fragile X Syndrome - Overview

Fragile X Syndrome - Therapeutics Development

Fragile X Syndrome - Therapeutics Assessment

Fragile X Syndrome - Companies Involved in Therapeutics Development

Fragile X Syndrome - Drug Profiles

Fragile X Syndrome - Dormant Projects

Fragile X Syndrome - Discontinued Products

Fragile X Syndrome - Product Development Milestones

Appendix

List of Tables

Number of Products under Development for Fragile X Syndrome, H2 2018

Number of Products under Development by Companies, H2 2018

Number of Products under Development by Companies, H2 2018 (Contd..1), H2 2018

Number of Products under Development by Universities/Institutes, H2 2018

Products under Development by Companies, H2 2018

Products under Development by Companies, H2 2018 (Contd..1), H2 2018

Products under Development by Universities/Institutes, H2 2018

Number of Products by Stage and Target, H2 2018

Number of Products by Stage and Mechanism of Action, H2 2018

Number of Products by Stage and Route of Administration, H2 2018

Number of Products by Stage and Molecule Type, H2 2018

Fragile X Syndrome - Pipeline by Aelis Farma SAS, H2 2018

Fragile X Syndrome - Pipeline by Anavex Life Sciences Corp, H2 2018

Fragile X Syndrome - Pipeline by Confluence Pharmaceuticals LLC, H2 2018

Fragile X Syndrome - Pipeline by DRI Biosciences Corp, H2 2018

Fragile X Syndrome - Pipeline by Eli Lilly and Co, H2 2018

Fragile X Syndrome - Pipeline by Epigen Biosciences Inc, H2 2018

Fragile X Syndrome - Pipeline by Fulcrum Therapeutics Inc, H2 2018

Fragile X Syndrome - Pipeline by GlaxoSmithKline Plc, H2 2018

Fragile X Syndrome - Pipeline by GW Pharmaceuticals Plc, H2 2018

Fragile X Syndrome - Pipeline by Healx Ltd, H2 2018

Fragile X Syndrome - Pipeline by Marinus Pharmaceuticals Inc, H2 2018

Fragile X Syndrome - Pipeline by NeuCyte Inc, H2 2018

Fragile X Syndrome - Pipeline by Neuren Pharmaceuticals Ltd, H2 2018

Fragile X Syndrome - Pipeline by Neuron Biopharma SA, H2 2018

Fragile X Syndrome - Pipeline by Novartis AG, H2 2018

Fragile X Syndrome - Pipeline by Ovid Therapeutics Inc, H2 2018

Fragile X Syndrome - Pipeline by Sage Therapeutics Inc, H2 2018

Fragile X Syndrome - Pipeline by Sentinel Oncology Ltd, H2 2018

Fragile X Syndrome - Pipeline by Tetra Discovery Partners LLC, H2 2018

Fragile X Syndrome - Pipeline by Zynerba Pharmaceuticals Inc, H2 2018

Fragile X Syndrome - Dormant Projects, H2 2018

Fragile X Syndrome - Dormant Projects, H2 2018 (Contd..1), H2 2018

Fragile X Syndrome - Discontinued Products, H2 2018

List of Figures

Number of Products under Development for Fragile X Syndrome, H2 2018

Number of Products under Development by Companies, H2 2018

Number of Products by Top 10 Targets, H2 2018

Number of Products by Stage and Top 10 Targets, H2 2018

Number of Products by Top 10 Mechanism of Actions, H2 2018

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2018

Number of Products by Routes of Administration, H2 2018

Number of Products by Stage and Routes of Administration, H2 2018

Number of Products by Molecule Types, H2 2018

Number of Products by Stage and Molecule Types, H2
Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4
  • Aelis Farma SAS
  • Anavex Life Sciences Corp
  • Confluence Pharmaceuticals LLC
  • DRI Biosciences Corp
  • Eli Lilly and Co
  • Epigen Biosciences Inc
  • Fulcrum Therapeutics Inc
  • GlaxoSmithKline Plc
  • GW Pharmaceuticals Plc
  • Healx Ltd
  • Marinus Pharmaceuticals Inc
  • NeuCyte Inc
  • Neuren Pharmaceuticals Ltd
  • Neuron Biopharma SA
  • Novartis AG
  • Ovid Therapeutics Inc
  • Sage Therapeutics Inc
  • Sentinel Oncology Ltd
  • Tetra Discovery Partners LLC
  • Zynerba Pharmaceuticals Inc
Note: Product cover images may vary from those shown
5 of 4
Note: Product cover images may vary from those shown
Order Online - visit: https://www.researchandmarkets.com/reports/4649592
Adroll
adroll